1.Expression of SARS-CoV nucleocapsid protein in Bac-to-Bac Baculovirus System and antigenic analysis
Li HUANG ; Zhiwu YU ; Yuxian PAN ; Liwen QIU ; Wei HAO ; Xixia DING ; Xiaoyao CHE ; Nan YU
Chinese Journal of Immunology 2014;(6):721-725
Objective:To express SARS-CoV nucleocapsid protein in Bac-to-Bac Baculovirus Expression System and analyze the antigenicity of the recombinant protein.Methods: The SARS-CoV nucleocapsid gene was amplified by PCR.The PCR product digested with BamHⅠand SalⅠrestriction endonucleases was cloned into vector pFastBac HTC of Bac-to-Bac Baculovirus expression system.Recombinant plasmid was transformed DH 10Bac cells to obtain the recombinant Bacmid DNA.Recombinant Bacmid DNA was transferred into Sf9 cells which were inducted to express the recombinant protein in High Five cells.After purified by Ni affinity chroma-tography ,the antigenicity of the recombinant protein was analyzed by Western blot and ELISA.Results:Recombinant plasmid was con-structed successfully.The recombinant protein with the relative molecular mass of 48 kD was efficiently expressed in High Five cells and purified successfully by Ni affinity chromatography.Western blot and ELISA analysis showed that the recombinant protein could be spe -cifically recognized by the monoclonal antibody to SARS-CoV N protein and immune serum from rabbits ,respectively.The recombinant protein can specifically reacted with serum from SARS patients ,not with serum from healthy persons and patients infected with hCoV-229 E and hCoV-OC43.Conclusion: SARS-CoV nucleocapsid protein has been expressed successfully in the Bac-to-Bac Baculovirus Expression System ,and obtained good antigenicity.It is preliminary deemed that it can't reacted with serum from patients infected with hCoV-229E and hCoV-OC43.
2.Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis.
Lei CHENG ; Jianjun CHEN ; Qingling FU ; Shaoheng HE ; Huabin LI ; Zheng LIU ; Guolin TAN ; Zezhang TAO ; Dehui WANG ; Weiping WEN ; Rui XU ; Yu XU ; Qintai YANG ; Chonghua ZHANG ; Gehua ZHANG ; Ruxin ZHANG ; Yuan ZHANG ; Bing ZHOU ; Dongdong ZHU ; Luquan CHEN ; Xinyan CUI ; Yuqin DENG ; Zhiqiang GUO ; Zhenxiao HUANG ; Zizhen HUANG ; Houyong LI ; Jingyun LI ; Wenting LI ; Yanqing LI ; Lin XI ; Hongfei LOU ; Meiping LU ; Yuhui OUYANG ; Wendan SHI ; Xiaoyao TAO ; Huiqin TIAN ; Chengshuo WANG ; Min WANG ; Nan WANG ; Xiangdong WANG ; Hui XIE ; Shaoqing YU ; Renwu ZHAO ; Ming ZHENG ; Han ZHOU ; Luping ZHU ; Luo ZHANG
Allergy, Asthma & Immunology Research 2018;10(4):300-353
Allergic rhinitis (AR) is a global health problem that causes major illnesses and disabilities worldwide. Epidemiologic studies have demonstrated that the prevalence of AR has increased progressively over the last few decades in more developed countries and currently affects up to 40% of the population worldwide. Likewise, a rising trend of AR has also been observed over the last 2–3 decades in developing countries including China, with the prevalence of AR varying widely in these countries. A survey of self-reported AR over a 6-year period in the general Chinese adult population reported that the standardized prevalence of adult AR increased from 11.1% in 2005 to 17.6% in 2011. An increasing number of original articles and imporclinical trials on the epidemiology, pathophysiologic mechanisms, diagnosis, management and comorbidities of AR in Chinese subjects have been published in international peer-reviewed journals over the past 2 decades, and substantially added to our understanding of this disease as a global problem. Although guidelines for the diagnosis and treatment of AR in Chinese subjects have also been published, they have not been translated into English and therefore not generally accessible for reference to non-Chinese speaking international medical communities. Moreover, methods for the diagnosis and treatment of AR in China have not been standardized entirely and some patients are still treated according to regional preferences. Thus, the present guidelines have been developed by the Chinese Society of Allergy to be accessible to both national and international medical communities involved in the management of AR patients. These guidelines have been prepared in line with existing international guidelines to provide evidence-based recommendations for the diagnosis and management of AR in China.
Adult
;
Asian Continental Ancestry Group*
;
China
;
Comorbidity
;
Developed Countries
;
Developing Countries
;
Diagnosis*
;
Epidemiologic Studies
;
Epidemiology
;
Global Health
;
Humans
;
Hypersensitivity*
;
Prevalence
;
Rhinitis, Allergic*
3.Optimization of the Preparation Technology of Syzygium aromaticum Oil Dropping Pills
Zhuo DU ; Xiaoyao YU ; Cuiqiong KUANG ; Yufang MO ; Baozhu ZHOU ; Lu LIU ; Haiyi LI ; Jialiang GUO
China Pharmacy 2019;30(24):3360-3363
OBJECTIVE: To establish the method for content determination of eugenol in Syzygium aromaticum oil dropping pills, and to optimize the preparation technology. METHODS: The content of eugenol in S. aromaticum oil dropping pills was determined by UV spectrophotometry. Based on single factor test, using the percentage of drugs in total amount, liquid temperature, falling distance of condensate, liquid drop distance as factors, taking the roundness, weight and hardness difference and comprehensive score as factors, L9(34) orthogonal design test was adopted to optimize the preparation process. RESULTS: The linear range of eugenol was 15.15-45.45 μg/mL(r=0.999 6); RSDs of precision, stability and reproducibility tests were all lower than 1%; the recoveries were 97.41%-100.59%(RSD=1.35%, n=6). The optimal preparation technology included that the percentage of drugs in total amount was 5%; liquid temperature was 80 ℃; falling distance of condensate was 13 cm; liquid drop distance was 6 cm. The dropping pills had smooth appearance, good roundness and moderate hardness; the average content of engenol was 4.073%(RSD=0.35%,n=6). CONCLUSIONS: The established method is simple, and can be used for the content determination of eugenol in S. aromaticum oil dropping pills. The optimal preparation technology is stable and feasible.
4.Recurrent hypertriglyceridemic acute pancreatitis in an adult patient caused by the de novo mutation of p.K327N in the GPD1 gene: A case report
Xiaoyao LI ; Jianfeng DUAN ; Dacheng WANG ; Xiancheng CHEN ; Beiyuan ZHANG ; Wenkui YU
Journal of Clinical Hepatology 2024;40(2):361-364
Hypertriglyceridemia (HTG) is the second leading cause of acute pancreatitis in China and can be caused by primary factors, namely gene mutations, which may lead to recurrent hypertriglyceridemic acute pancreatitis (HTG-AP) and difficulties in effective control of triglyceride. This article reports an adult Chinese male patient who experienced eight attacks of HTG-AP and was found to carry a de novo heterozygous mutation, p.K327N, of the GPD1 gene, which may cause the persistent high level of triglyceride and recurrent attacks of HTG-AP.